Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751)

NCT01469182 is registered in ClinicalTrials.gov with ALK-Abelló A/S as lead sponsor.

NCT NCT01469182
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01469182 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Allergy Immunotherapy Tablet (SCH 39641/MK-3641) Treatment in Ragweed Allergic Adults (Phase 3, Protocol No.P05751)
Lead sponsor
ALK-Abelló A/S
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2011
Completion date
April 30, 2012
Enrollment
914 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

allergy